Cover Image

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma

Clinical trials of anti-CD19 chimeric antigen receptor T (CART19) cell therapy have shown high overall response rates in patients with relapsed/refractory B-cell malignancies. CART19 cell therapy has been approved by the US Food and Drug Administration for patients who relapsed less than 12 months a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shuto Negishi (Author), James H. Girsch (Author), Elizabeth L. Siegler (Author), Evandro D. Bezerra (Author), Kotaro Miyao (Author), R. Leo Sakemura (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas
by: Pedro Justicia-Lirio, et al.
Published: (2024)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
by: Vairy S, et al.
Published: (2018)

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
by: Forsberg MH, et al.
Published: (2018)

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
by: Jain MD, et al.
Published: (2018)

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma
by: Brendan Bender, et al.
Published: (2024)

Diffuse large B cell lymphoma of the cervix with rectal involvement
by: Elena Igwe, et al.
Published: (2014)

Relapsed primary cutaneous diffuse large B-cell lymphoma, leg type
by: Shaohua Wu, et al.
Published: (2017)

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
by: Hai-ping Dai, et al.
Published: (2022)

Relapsed angioimmunoblastic T-cell lymphoma presenting as psoriasiform dermatitis
by: Spencer McClure, MD, et al.
Published: (2023)

B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature
by: Jamil Kazma, et al.
Published: (2019)

Silent presentation of B-Cell Lymphoma in the mandible
by: H. Javed, et al.
Published: (2022)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma
by: Maria Giraudo, et al.
Published: (2024)

Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
by: Sally D Miller, et al.
Published: (2022)

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review
by: Bayarmagnai Weinstein, et al.
Published: (2021)

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: Report of a case in the oral cavity
by: Jumana M Jaradat, et al.
Published: (2013)

Substance P Increases Cell-Surface Expression of CD74 (Receptor for Macrophage Migration Inhibitory Factor): In Vivo Biotinylation of Urothelial Cell-Surface Proteins
by: Katherine L. Meyer-Siegler, et al.
Published: (2009)

The role of dermatoscopy and reflectance confocal microscopy in the assessment of relapsing secondary cutaneous follicular B-cell lymphoma
by: Alessandro Laghi, MD, et al.
Published: (2022)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
by: Songmi Wang, et al.
Published: (2023)

CAR T-cell immunotherapy of B-cell malignancy: the story so far
by: Leena Halim, et al.
Published: (2020)

A 53-Year-Old Male with Relapsed Diffuse Large B-Cell Lymphoma on Chemotherapy with a New Leg Lesion
by: Connie R. Shi, et al.
Published: (2017)

SOS: Medien des Überlebens Die existenzielle Bedeutung von Lebenszeichen in Notfällen
by: Siegler, Martin
Published: (2023)

SOS: Medien des Überlebens Die existenzielle Bedeutung von Lebenszeichen in Notfällen
by: Siegler, Martin
Published: (2023)

Loss of CD20 expression in relapsed diffuse large b-cell lymphoma: Clinical significance of an uncommon pathological finding
by: Subhashis Mitra, et al.
Published: (2016)

Engineering CAR-T cells
by: Cheng Zhang, et al.
Published: (2017)

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors' observation
by: L. G. Gorenkova, et al.
Published: (2019)

CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma
by: Sun J, et al.
Published: (2021)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
by: Ma X, et al.
Published: (2020)

Educational Case: Gastric High-Grade B-Cell Lymphoma With and Gene Rearrangement (Double-Hit Lymphoma)
by: Elham Vali Betts MD, et al.
Published: (2020)

Mosquito Bite-Induced Localized NK/T-Cell Lymphoma Relapsed in a Patient with Complete Remission of Extranodal NK/T-Cell Lymphoma, Nasal Type
by: Makoto Kondo, et al.
Published: (2019)

Donor T cells for CAR T cell therapy
by: Tiffany C. Y. Tang, et al.
Published: (2022)

The Mutation of BTG2 Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma
by: Guo D, et al.
Published: (2022)

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
by: Vivian Jiang, et al.
Published: (2024)

Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting
by: Niamh Carey, et al.
Published: (2023)

An Isolated Testicular Relapse of Burkitt's Lymphoma
by: Young Suk Kwon MD, et al.
Published: (2019)

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
by: Amber Loren O. King, BA, et al.
Published: (2021)

A case of B-cell lymphoblastic leukemia cutis flaring following CAR T-cell therapy in a patient with refractory acute lymphoblastic leukemia
by: Pranav Puri, BA, et al.
Published: (2021)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015)

Generating CAR T cells from tumor-infiltrating lymphocytes
by: Jane K. Mills, et al.
Published: (2021)

Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse
by: Christopher N. Nguyen, BA, et al.
Published: (2021)

Immunogenicity in CAR T cell immunotherapy
by: Emily Yu
Published: (2023)